TY - JOUR
T1 - A protein-truncating R179X variant in RNF186 confers protection against ulcerative colitis
AU - UK IBD Genetics Consortiumw
AU - NIDDK IBD Genetics Consortium
AU - Rivas, Manuel A.
AU - Graham, Daniel
AU - Sulem, Patrick
AU - Stevens, Christine
AU - Desch, A. Nicole
AU - Goyette, Philippe
AU - Gudbjartsson, Daniel
AU - Jonsdottir, Ingileif
AU - Thorsteinsdottir, Unnur
AU - Degenhardt, Frauke
AU - Mucha, Sören
AU - Kurki, Mitja I.
AU - Li, Dalin
AU - D'Amato, Mauro
AU - Annese, Vito
AU - Vermeire, Severine
AU - Weersma, Rinse K.
AU - Halfvarson, Jonas
AU - Paavola-Sakki, Paulina
AU - Lappalainen, Maarit
AU - Lek, Monkol
AU - Cummings, Beryl
AU - Tukiainen, Taru
AU - Haritunians, Talin
AU - Halme, Leena
AU - Koskinen, Lotta L.E.
AU - Ananthakrishnan, Ashwin N.
AU - Luo, Yang
AU - Heap, Graham A.
AU - Visschedijk, Marijn C.
AU - MacArthur, Daniel G.
AU - Neale, Benjamin M.
AU - Ahmad, Tariq
AU - Anderson, Carl A.
AU - Brant, Steven R.
AU - Duerr, Richard H.
AU - Silverberg, Mark S.
AU - Cho, Judy H.
AU - Palotie, Aarno
AU - Saavalainen, Päivi
AU - Kontula, Kimmo
AU - Färkkilä, Martti
AU - McGovern, Dermot P.B.
AU - Franke, Andre
AU - Stefansson, Kari
AU - Rioux, John D.
AU - Xavier, Ramnik J.
AU - Daly, Mark J.
AU - Barrett, J.
AU - De Lane, K.
N1 - Funding Information:
M.J.D. is supported by grants from the following: the National Institute of Diabetes and Digestive and Kidney Disease (NIDDK) and the National Human Genome Research Institute (NHGRI; DK043351, DK064869 and HG005923); the Crohns and Colitis Foundation (3765); the Leona M. & Harry B. Helmsley Charitable Trust (2015PGIBD001); and Amgen (2013583217). R.J.X. is supported by grants from Amgen (2013583217) and CCFA (3765). J.D.R. is funded by grants from NIDDK (DK064869 and DK062432). IBD Research at Cedars-Sinai is supported by grant PO1DK046763 and the Cedars-Sinai F. Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute Research Funds. D.P.B.M. is supported by DK062413, AI067068 and U54DE023789-01; grant 305479 from the European Union; and The Leona M. and Harry B. Helmsley Charitable Trust and the Crohn's and Colitis Foundation of America. S.R.B. is support by an NIH U01 grant (DK062431). The sequencing of UK patients was funded by a grant from the Medical Research Council, UK (MR/J00314X/1). The UK10K project was funded by the Wellcome Trust (WT091310). C.A.A. is funded by the Wellcome Trust (098051). J.C. is supported by grants from NIH (U01 DK062429, U01 DK062422, R01 DK092235, SUCCESS). R.H.D. is supported by NIH grant U01 DK062420 and the Inflammatory Bowel Disease Genetic Research Chair at the University of Pittsburgh.
PY - 2016/8/9
Y1 - 2016/8/9
N2 - Protein-truncating variants protective against human disease provide in vivo validation of therapeutic targets. Here we used targeted sequencing to conduct a search for protein-truncating variants conferring protection against inflammatory bowel disease exploiting knowledge of common variants associated with the same disease. Through replication genotyping and imputation we found that a predicted protein-truncating variant (rs36095412, p.R179X, genotyped in 11,148 ulcerative colitis patients and 295,446 controls, MAF=up to 0.78%) in RNF186, a single-exon ring finger E3 ligase with strong colonic expression, protects against ulcerative colitis (overall P=6.89 × 10 â '7, odds ratio=0.30). We further demonstrate that the truncated protein exhibits reduced expression and altered subcellular localization, suggesting the protective mechanism may reside in the loss of an interaction or function via mislocalization and/or loss of an essential transmembrane domain.
AB - Protein-truncating variants protective against human disease provide in vivo validation of therapeutic targets. Here we used targeted sequencing to conduct a search for protein-truncating variants conferring protection against inflammatory bowel disease exploiting knowledge of common variants associated with the same disease. Through replication genotyping and imputation we found that a predicted protein-truncating variant (rs36095412, p.R179X, genotyped in 11,148 ulcerative colitis patients and 295,446 controls, MAF=up to 0.78%) in RNF186, a single-exon ring finger E3 ligase with strong colonic expression, protects against ulcerative colitis (overall P=6.89 × 10 â '7, odds ratio=0.30). We further demonstrate that the truncated protein exhibits reduced expression and altered subcellular localization, suggesting the protective mechanism may reside in the loss of an interaction or function via mislocalization and/or loss of an essential transmembrane domain.
UR - http://www.scopus.com/inward/record.url?scp=84981165781&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84981165781&partnerID=8YFLogxK
U2 - 10.1038/ncomms12342
DO - 10.1038/ncomms12342
M3 - Article
C2 - 27503255
AN - SCOPUS:84981165781
SN - 2041-1723
VL - 7
JO - Nature Communications
JF - Nature Communications
M1 - 12342
ER -